CellCap Therapeutics

CellCap Therapeutics is a biotechnology company focused on the discovery and development of targeted therapies for the selective elimination of senescent cells, often called "zombie cells." Spun out from the University of Leicester, the company utilizes its proprietary platform to map the senescent cell "surfaceome" and identify unique markers not present on healthy cells. Their primary therapeutic approach involves developing monoclonal antibodies designed to treat chronic conditions driven by cell senescence, such as idiopathic pulmonary fibrosis and oncology-related tissue damage. By providing precision targeting, CellCap aims to overcome the toxicity issues associated with first-generation, broad-spectrum senolytic drugs. The company represents a specialized entry in the emerging geroscience field, focusing on high-unmet-need age-related pathologies.